ARS Pharmaceuticals Launches Pre-Ordering Services For neffy To Help Patients Access The Treatment For Type I Allergic Reactions, Including Anaphylaxis

Patients can request a prescription from their existing healthcare provider, or meet with a physician virtually, to request a prescription for neffy ahead of product availability expected by late September

 

Visit neffy.com to pre-order and access comprehensive patient assistance programs available to patients and caregivers

Patients who already have a prescription can work with their healthcare provider to request neffy through the neffyConnect service and BlinkRx

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today pre-ordering services for neffy® (epinephrine nasal spray), ensuring swift access upon availability, expected in late September. Recently, the U.S. Food and Drug Administration (FDA) approved neffy for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). Pre-ordering can begin immediately via neffy.com.